Asnaghi M Adelaide, Power Laura, Barbero Andrea, Haug Martin, Köppl Ruth, Wendt David, Martin Ivan
Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
Front Bioeng Biotechnol. 2020 Apr 7;8:283. doi: 10.3389/fbioe.2020.00283. eCollection 2020.
The definition of quality controls for cell therapy and engineered product manufacturing processes is critical for safe, effective, and standardized clinical implementation. Using the example context of cartilage grafts engineered from autologous nasal chondrocytes, currently used for articular cartilage repair in a phase II clinical trial, we outlined how gene expression patterns and generalized linear models can be introduced to define molecular signatures of identity, purity, and potency. We first verified that cells from the biopsied nasal cartilage can be contaminated by cells from a neighboring tissue, namely perichondrial cells, and discovered that they cannot deposit cartilaginous matrix. Differential analysis of gene expression enabled the definition of identity markers for the two cell populations, which were predictive of purity in mixed cultures. Specific patterns of expression of the same genes were significantly correlated with cell potency, defined as the capacity to generate tissues with histological and biochemical features of hyaline cartilage. The outlined approach can now be considered for implementation in a good manufacturing practice setting, and offers a paradigm for other regenerative cellular therapies.
细胞治疗和工程产品制造过程的质量控制定义对于安全、有效和标准化的临床应用至关重要。以目前用于II期临床试验中关节软骨修复的自体鼻软骨细胞工程化软骨移植为例,我们概述了如何引入基因表达模式和广义线性模型来定义同一性、纯度和效力的分子特征。我们首先证实,活检鼻软骨中的细胞可能会被邻近组织的细胞污染,即软骨膜细胞,并发现它们不能沉积软骨基质。基因表达的差异分析能够定义这两种细胞群体的同一性标记,这些标记可预测混合培养物中的纯度。相同基因的特定表达模式与细胞效力显著相关,细胞效力定义为生成具有透明软骨组织学和生化特征的组织的能力。现在可以考虑在良好生产规范环境中实施所概述的方法,并为其他再生细胞疗法提供范例。